Journal for ImmunoTherapy of Cancer (Jun 2020)
Retracted
- Samah Elsaadi,
- Kristine Misund,
- Pegah Abdollahi,
- Esten Nymoen Vandsemb,
- Siv Helen Moen,
- Anna Kusnierczyk,
- Geir Slupphaug,
- Therese Standal,
- Anders Waage,
- Tobias S Slørdahl,
- Even Rustad,
- Anders Sundan,
- Carl Hay,
- Alwin G Schuller,
- Alexandra Borodovsky,
- Eline Menu,
- Magne Børset,
- Anne Marit Sponaas
Affiliations
- Samah Elsaadi
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Kristine Misund
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Pegah Abdollahi
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Esten Nymoen Vandsemb
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Siv Helen Moen
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Anna Kusnierczyk
- PROMEC, Department for Clinical and Molecular Medicine, NTNU, Trondheim, Norway
- Geir Slupphaug
- PROMEC, Department for Clinical and Molecular Medicine, NTNU, Trondheim, Norway
- Therese Standal
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Anders Waage
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Tobias S Slørdahl
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Even Rustad
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Anders Sundan
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Carl Hay
- Oncology R&D, AstraZeneca Medimmune, Gaithersburg, Maryland, USA
- Alwin G Schuller
- Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA
- Alexandra Borodovsky
- Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA
- Eline Menu
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Brussel, Massachusetts, Belgium
- Magne Børset
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- Anne Marit Sponaas
- Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- DOI
- https://doi.org/10.1136/jitc-2020-0637-6ret
- Journal volume & issue
-
Vol. 8,
no. 1
Abstract
No abstracts available.